News

Menarini catches ADC fever
Enlarge image

BusinessItalyUK

Menarini catches ADC fever

30.10.2012 - Italian Menarini Group and Oxford Biotherapeutics want to jointly develop five antibody-based drugs. The deal is worth €800m.

„I am very pleased to announce this novel strategic alliance, which foresees the development and manufacture of up to five cancer treatment programmes and a total investment of €800m“, said Alberto Giovanni Aleotti, a member of the Board of Florence-based Menarini Group, on 29 October 2012. The ally comes from the UK. The biotech company Oxford Biotherapeutics (OBT) will contribute five of its about 25 antibody and antibody drug conjugate (ADC) programmes, each of which addresses a different cancer indication via a different novel oncology target. Menarini, however, brings in its clinical knowledge so that under the agreements of the collaboration, the Italian pharma corporation will lead the efforts in the manufacture and clinical development of each programme, while OBT will provide the proprietary cancer target, antibody and arming technologies.

The companies plan to work together for about 10 years. Once clinical proof of concept of one or the other programme has been achieved, OBT will complete the clinical development and commercialise these novel antibody-based products in North America and Japan, whilst Menarini will develop and commercialise the products in Europe, CIS, Asia and Latin America. Menarini’s fortitude comes a bit as a surprise because the pharma business has already burned its fingers in antibody-based drugs: Just 16 months ago a Phase III trial of abagovomab, a mouse anti-idiotype monoclonal antibody mimicking the CA-125 antigen found on ovarian cancer cells, could not fulfil the expectations raised in previous studies.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/menarini-catches-adc-fever.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%

FLOP

  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%

TOP

  • SYNGENTA430.80 CHF32.0%
  • EVOLVA1.84 CHF20.3%
  • BASILEA132.00 CHF16.7%

FLOP

  • CYTOS0.66 CHF-32.7%
  • MEDIGENE8.43 EUR-19.3%
  • 4SC4.65 EUR-10.6%

TOP

  • WILEX3.95 EUR393.7%
  • FORMYCON28.39 EUR318.7%
  • 4SC4.65 EUR307.9%

FLOP

  • MOLOGEN5.05 EUR-52.5%
  • PAION2.54 EUR-26.8%
  • BIOFRONTERA2.29 EUR-25.6%

No liability assumed, Date: 28.05.2015